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CONTRIBUTION OF MONOAMINERGIC MECHANISMS TO THE DISCRIMINATIVE
STIMULUS EFFECTS OF 3,4-METHYLENEDIOXYPYROVALERONE (MDPV)
IN SPRAGUE-DAWLEY RATS

Harmony I. Risca, M.A.
Western Michigan University, 2018

3,4-Methylenedioxypyrovalerone (MDPV) is a popular synthetic cathinone reported to
have a high abuse potential and comparable pharmacological actions to those of cocaine. The
aim of this study was to evaluate a variety of monoaminergic agents for substitution,
potentiation, or antagonism in rats trained to discriminate MDPV. Male Sprague-Dawley rats
were trained to discriminate 0.5 mg/kg MDPV and a variety of monoaminergic drugs were tested
for substitution and/or potentiation of the MDPV cue. In separate experiments, stimulus
antagonism tests were conducted with selected dopamine antagonists or serotonin antagonists in
rats trained to discriminate 1 mg/kg MDPV. Full substitution for MDPV was observed with
cocaine, (±)-MDMA, (+)-MDMA and (±)-MDA; (+)-MDA produced significant partial
substitution, whereas (-)-MDMA or (-)-MDA did not substitute. Although neither GBR 12909
nor desipramine substituted for MDPV, these substances potentiated MDPV discrimination. Sch
23390 and haloperidol both dose-dependently attenuated MDPV discrimination, whereas none of
the 5-HT antagonists tested altered MDPV discrimination. These findings indicate MDPV’s
interoceptive stimulus effects are mediated predominantly by dopaminergic actions, although
serotonergic and/or noradrenergic modulation of these effects cannot be ruled out. Further
investigations into the precise neurochemical actions responsible for MDPV discrimination may
serve to inform medication discovery and development for the treatment of MDPV abuse.
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CHAPTER 1
INTRODUCTION
Synthetic Cathinones
Substance abuse and addiction have long been a public health concern, but the recent
popularity in the marketing of synthetic alternatives as “legal highs” has become a worldwide
health concern. One of the three most common classes of “new psychoactive substances”
includes the synthetic cathinones (“bath salts”) (Rosenbaum & Carreiro, 2012). Although most
synthetic cathinones used today are manufactured by foreign laboratories and sold via the
internet, cathinone is a naturally occurring psychoactive substance that can be found in the leaves
of the khat (Catha edulis) plant (Baumann et al., 2017; Valente et al., 2014). Khat leaves and
twigs have been chewed for centuries in East African countries for their mild amphetamine-like
euphoric effects long before synthetic cathinones emerged in recreational drug markets (Valente
et al., 2014).
The initial popularity of synthetic cathinone use arose in response to attempts to elude
legal restrictions on other popular drugs of abuse, such as cocaine and 3,4methylenedioxymethamphetamine (MDMA) (Valente et al., 2014). Although synthetic
cathinones are now listed as schedule I controlled substances in the United States, illicit use
remains popular among recreational users. Emergency room visits and poison control reports
related to synthetic cathinones (U.S. Department of Justice National Drug Intelligence Center
(NDIC), 2011) have recently raised public health awareness regarding these substances.
3,4-Methylenedioxypyrovalerone (MDPV) is one of several synthetic cathinone
derivatives and a popular constituent of illicit “bath salts” commonly associated with emergency
department reports related to “bath salt” abuse (Centers for Disease Control and Prevention
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(CDC), 2011; Froberg et al., 2015; NDIC, 2011; Spiller et al., 2011). Physiological effects of
MDPV toxicity include tachycardia, hypertension, arrhythmias, hyperthermia, sweating,
rhabdomyolysis, seizures, cerebral edema, cardiorespiratory collapse, myocardial infarction, and
death. In addition to life-threatening physiological symptoms, reports of behavioral effects
including panic attacks, anxiety, agitation, severe paranoia, hallucinations, psychosis, suicidal
ideation, self- mutilation, and aggression have been noted (CDC, 2011; Ross et al., 2012).
Neuropharmacology of MDPV
Previous research indicates MDPV has neuropharmacological and behavioral properties
comparable to those of cocaine, a highly addictive central nervous system stimulant derived from
the leaves of the coca plant, and the psychedelic-stimulant and popular club drug MDMA,
"Ecstasy" (Aarde et al., 2015; Cameron et al., 2013; Fantegrossi et al., 2013; Gatch et al., 2013;
Ross et al., 2012). Studies using established drug discovery techniques, such as in vitro receptor
binding, have revealed that MDPV potently blocks dopamine and norepinephrine uptake, with
relatively weaker effects on serotonin uptake (Simmler et al., 2013; Eshleman et al., 2013).
Compared to cocaine, MDPV is up to 50-fold more potent at the dopamine transporter (DAT),
approximately 10-fold more potent at the norepinephrine transporter (NET), and 10-fold less
potent at the serotonin transporter (Baumann et al., 2013). This enhanced potency may be
responsible for the severity of physiological and behavioral reports associated with MDPV
toxicity (Froberg et al., 2015; Spiller et al., 2011).
Psychopharmacology of MDPV
The abuse liability of MDPV has been confirmed by several preclinical reports that this
substance establishes conditioned place preference (King et al., 2015a; 2015b) and maintains
self-administration in rodents (Schindler et al., 2016; Aarde et al., 2013; Aarde et al., 2015;
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Watterson et al., 2014). A recent report indicates MDPV is approximately 10-fold more potent
and approximately three-fold more effective at maintaining responding under a progressive ratio
schedule compared to cocaine (Gannon et al., 2017). Determining the precise neurochemical
actions responsible for MDPV’s abuse liability is critical to the discovery and development of
treatment medications.
Drug Discrimination Assay
Drug discrimination is a widely accepted in vivo preclinical assay used to evaluate the
neurochemical substrates underlying the interoceptive stimulus effects of drugs (Baker, 2017).
Four basic components are typically involved in drug discrimination paradigms: ‘1) the subject
and their “motivational condition”; 2) drug dose that exerts an effect on the subject, or its
vehicle, and precedes a response by the subject; 3) an appropriate (or correct) response; and 4)
presentation of reinforcement’ (Glennon & Young, 2011, p. 8). A drug is established as a
discriminative stimulus when drug administration consistently precedes reinforcement of a
particular response (e.g., right lever press) and never precedes reinforcement of an alternative
response (e.g., left lever press). Subjects are most typically trained to discriminate the centrallymediated effects of a drug from vehicle (Stolerman et al., 1999). Such training and methodology
allows for both qualitative and quantitative data to be collected, alluding to the stimulus
properties of a drug (Glennon & Young, 2011).
Drug Discrimination Studies with MDPV
Despite the predictive utility of the drug discrimination paradigm, few published studies
have employed such methods to train animals to discriminate MDPV. These studies have noted
similar interoceptive stimulus effects between MDPV and several established psychoactive
stimulants, such as methamphetamine, d-amphetamine, cocaine, and MDMA (Fantegrossi et al.,
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2013; Berquist & Baker, 2017). Some discrepancies between these studies are worth noting,
particularly with regard to stimulus substitution with MDMA. Fantegrossi reported full
substitution with MDMA in mice trained to discriminate 0.3 mg/kg MDPV, whereas Berquist
and Baker (2017) found that MDMA failed to fully substitute in rats trained to discriminate 0.3
mg/kg MDPV. Other methodological differences besides species (e.g., reinforcer type and
reinforcement schedule) were noted between these studies and could contribute to the
inconsistent findings.
Several other studies have evaluated MDPV for substitution in animals trained to
discriminate other stimulants. Full substitution was observed with MDPV in rats trained to
discriminate d-amphetamine (Harvey et al., 2017) or cocaine (Gatch et al., 2013; Gannon et al.,
2016), although only partial substitution was observed with MDPV in rats trained to discriminate
MDMA (Harvey & Baker, 2016).
Complex Interoceptive Stimulus Studies of MDMA
The equivocal findings regarding substitution between MDPV and MDMA may be
related to MDMA’s complex cues involving serotonergic and dopaminergic actions that may be
dissociable and dependent on discrimination training methods (Baker et al., 1995; Goodwin &
Baker, 2000; Goodwin et al. 2003). Previous studies utilizing drug discrimination procedures to
assess the stereoisomers of MDMA and 3,4-Methylenedioxyamphetamine (MDA) suggest that
the discriminative stimulus effects of (+)-MDA are more similar to those of amphetamine,
whereas the discriminative stimulus effects of (-)-MDA, and (-)-MDMA are more comparable to
those of LSD (Baker et al., 1995; Broadbent et al., 1992; Callahan & Appel, 1988; Glennon &
Young, 1984).
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Research Objective
In an effort to evaluate the neurochemical actions underlying the discriminative stimulus
effects of MDPV the present study conducted two separate experiments (Experiment 1 and
Experiment 2) using two different doses of MDPV (0.5 and 1.0 mg/kg) previously studied in our
lab. Experiment 1 consisted of stimulus substitution with MDMA, MDA, and their optical
isomers, along with monoamine reuptake inhibitors with varying selectivity for DAT, NET, or
SERT in rats trained to discriminate 0.5 mg/kg MDPV to aid in the classification of MDPV’s
interoceptive effects. Additionally, Experiment 2 assessed dopamine and serotonin antagonists
for attenuation of the MDPV cue in rats trained to discriminate 1.0 mg/kg MDPV.
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CHAPTER II
METHODS
Subjects
Fourteen male Sprague-Dawley rats (Experiment 1: n=7; Experiment 2: n=7) (Charles
River Laboratories, Wilmington, MA, USA) were housed individually in polycarbonate cages
with corncob bedding (Harlan Laboratories, Haslett, MI, USA) in animal facilities maintained at
constant 20 ± 2°C, with a humidity of 50 ± 5% under a 12:12 light/dark cycle (lights on from
07:00 to 19:00h). Animals were provided water ad libitum in home cages and fed restricted diets
of commercial rodent chow (Purina®, Richmond, IN, USA) to maintain 85-90% of free-feeding
weights (340-440g). All procedures were reviewed and approved by the Western Michigan
University Institutional Animal Care and Use Committee, and were in accordance with the
guidelines of the Guide for the Care and Use of Laboratory Animals (National Research Council
of the National Academies, 2011).
Apparatus
Training and testing procedures were conducted in seven standard operant conditioning
chambers equipped with three retractable levers, a food pellet dispenser and fan on the front
panel, a 28-V house light on the back panel, and housed within sound-attenuating shells (ENV001; Med Associates Inc., St. Albans, Vermont, USA). Experimental events were controlled
using Med-PC IV software (version IV; Med Associates Inc.). Dustless Precision Pellets (45 mg;
Product# F0021; BioServ, Flemington, NJ) were used as reinforcements for lever pressing.
Drugs
Cocaine-hydrochloride, 3,4-methylenedioxypyrovalerone-hydrochloride (MDPV),
(±)-3,4-methylenedioxymethamphetamine-hydrochloride (MDMA), (±)-3,4-
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methylenedioxyamphetamine-hydrochloride (MDA), and the optical isomers of MDMA and
MDA were provided by the National Institute on Drug Abuse Drug Control Supply Program
(Bethesda, MD). GBR 12909 bismethanesulfonate monohydrate was prepared in the Chemical
Biology Research Branch, National Institute on Drug Abuse and the National Institute on
Alcohol Abuse and Alcoholism. MDL 100,907, and WAY 100,635 were provided by the
National Institutes of Mental Health Chemical Synthesis and Drug Supply Program. Pirenperone
was purchased from Santa Cruz Biotechnology (Mississauga, ON). Desipramine-hydrochloride,
(+)-Sch 23390-hydrochloride, and haloperidol were purchased from Sigma-Aldrich ® (St. Louis,
MO). Haloperidol was dissolved in a few drops of 0.1 M HCl, diluted in sterile water, and the pH
was adjusted as needed with 0.1 M NaOH. Pirenperone was dissolved in 30% cyclodextrin (2hydroxypropyl-beta-cyclodextrin) at a concentration of 1 mg/ml and then diluted with sterile
water. MDL 100,907 was dissolved with a few drops of glacial acetic acid and diluted with
sterile water. All other drugs were dissolved in bacteriostatic 0.9% sodium chloride. All drugs
were administered by intraperitoneal (i.p.) injection at a volume of 1 ml/kg. The range of doses
and pre-session injection intervals for MDPV and all other compounds tested were selected
based on previous studies conducted in our laboratory.
Preliminary Training
Preliminary and discrimination training procedures were identical in Experiment 1 and
Experiment 2, apart from training dose, and were similar to previous studies previously
performed in the present lab (Berquist & Baker, 2017; Harvey & Baker, 2016). Initial training
involved two 60-min sessions, one per day for two consecutive days in which no levers were
presented and food pellets were delivered under a fixed-time 60 second (FT60”) schedule to
acclimated rats to the operant chambers and familiarize them towards the pellet dispenser.
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Subsequent training sessions lasted 20 minutes per day and were conducted 6-7 days a week. To
reduce the likelihood of lever bias, center levers were exclusively used during initial lever
training. Reinforcement was delivered under a fixed-ratio (FR) schedule that was gradually
incremented from FR 1 to FR 20. Once rats were reliably pressing the center lever on the FR 20
schedule, errorless training sessions began. During errorless training, rats were injected via i.p.
with either vehicle or drug prior to session depending on whether the left or right lever was
extended. Lever assignment to stimulus condition was counterbalanced among rats in each
experiment. Errorless sessions were conducted in the following order: V, V, D, D, V, D, V, V, D,
D, V, D. Discrimination training began once subjects were responding reliably on a FR 20
schedule on both the drug and vehicle-paired levers.
Discrimination Training
Discrimination training involved the simultaneous presentation of both levers in which
rats were trained to discriminate either 0.5 mg/kg MDPV (Experiment 1) or 1.0 mg/kg MDPV
(Experiment 2) from vehicle under a FR 20 schedule of food reinforcement. Drug and vehicle
training sessions alternated with the stipulation that the same stimulus condition occurred no
more than twice consecutively (e.g., D, D, V, D, V, V), but in no particular order. The
performance criteria for stimulus control was a minimum of eight out of ten consecutive
discrimination training sessions with 80% or higher correct lever responses prior to delivery of
the first reinforcer and for the total session.
After stimulus control was established, test sessions were conducted as described below
for each experiment. Test sessions were similar to training sessions, with the exception that
responses were not reinforced and sessions ended upon completion of the first FR 20 or after 20
minutes, whichever occurred first. Testing criteria between sessions required subjects to
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complete at least one drug and at least one vehicle training session consecutively with 80% or
higher injection-appropriate responding.
Experiment 1
Stimulus Substitution and Potentiation Tests
In rats trained to discriminate 0.5 mg/kg MDPV, the following drugs (doses, pre-injection
interval) were assessed for substitution: MDPV (0.05, 0.1, 0.5 mg/kg, 15 min), (±)-MDA, (±)MDMA, (+)-MDA, (-)-MDA, (+)-MDMA, (-)-MDMA (0.75, 1.5, 3.0 mg/kg, 15 min), GBR
12909 (5, 10, 20, 40 mg/kg, 30 min), cocaine (2.5, 5, 10, 20 mg/kg, 15 min), and desipramine
(0.0, 3.2, 5.6, 10 mg/kg, 30 min). Additionally, Sch 23390 (0.01, 0.03, 0.1 mg/kg, 30 min) was
assessed for antagonism of 0.5 mg/kg MDPV. Finally, desipramine (3.2 mg/kg, 30 min), GBR
12909 (40 mg/kg, 30 min), or vehicle were administered as a pretreatment to each MDPV dose
(0.05, 0.1, 0.5 mg/kg, 15 min) to assess potentiation of MDPV discrimination.
Experiment 2
Stimulus Antagonism Tests
After determination of the dose-response curve with MDPV (0.1, 0.3, 1.0 mg/kg, 15
min), the following drugs were assessed for antagonism of 1.0 mg/kg MDPV: Sch 23990 (0.01,
0.03, 0.1, 0.3 mg/kg, 30 min), haloperidol (0.125, 0.25, 0.5 mg/kg, 60 min), pirenperone (0.16,
0.32, 0.64 mg/kg, 60 min), MDL 100,907 (0.025, 0.05, 0.1 mg/kg, 60 min), and WAY 100,635
(0.4, 0.8, 1.6 mg/kg, 60 min).
Data Analysis
Stimulus control was determined as the number of sessions required for each subject to
meet specified criteria of 80% correct responses in a minimum of 8 of 10 consecutive sessions.
The number of sessions to criteria was determined from the first training session when both
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levers were present. For each test compound, the mean (±SEM) percentage of drug-lever
responses was determined for each dose. These data were analyzed with descriptive statistics and
plotted in dose response curves for visual analysis. Tests in which an animal emitted less than 10
total responses were excluded from the analysis of percentage drug-lever selection. Full
substitution by a test compound was defined as ≥ 80% drug-lever selection by any particular
dose. Partial substitution was defined as drug-lever selection between 40 and 80%. Full
antagonism by a test compound was defined as ≤ 20% drug-lever selection by any dose. Partial
antagonism was defined as between 20 and 60% drug-lever selection.
Response rates were expressed as the number responses emitted per second during test
sessions. For each test compound, the mean (±SEM) response rate was determined for each dose
and these data were plotted in dose response curves. Response rates were included in statistical
analyses regardless of the number of responses emitted. For each test compound, response rates
were statistically analyzed using a one-way repeated-measures (RM) analysis of variance
(ANOVA), followed by Dunnett’s multiple comparisons to compare each test dose to the saline
control. Graphical and statistical analyses were conducted using Prism GraphPad (Version 6.0).
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CHAPTER III
RESULTS
Discrimination Acquisition
Stimulus control was established by 0.5 mg/kg MDPV with rats in Experiment 1 within
26.7 (± 3.4, S.E.M.) training sessions (range 11-36). Rats used in the second experiment trained
to discriminate 1.0 mg/kg MDPV from saline established stimulus control within 15.3 (± 1.2,
SEM) training sessions (range 12-18).
Experiment 1
Stimulus Substitution
Dose-response curves generated from substitution tests with MDPV, MDMA, MDA and
the optical isomers of MDMA or MDA are displayed in Figure 1. MDPV produced dosedependent increases in MDPV-lever responses with minimal effects on response rate.
The MDMA and MDA enantiomers produced divergent results, with minimal MDPVlever selection produced by (-)-MDMA or (-)-MDA, partial substitution by (+)-MDA (60%), and
full substitution by (+)-MDMA (87%). The racemates produced full substitution with 83%
MDPV-lever selection by (±)-MDMA and 89% by (±)-MDA. A dose-dependent decrease in
response rate was observed with MDMA, MDA and their optical isomers. One-way RM
ANOVA found a statistically significant reduction in response rate by (-)-MDMA [F(3, 18) =
4.64, P < 0.05], (+)-MDA [F(3, 18) = 11.10, P < 0.001], (-)-MDA [F(3, 18) = 17.09, P < 0.0001]
as well as with (±)-MDMA [F(3, 18) = 10.10, P < 0.001] and (±)-MDA [F(3, 18) = 13.14, P <
0.0001]. Dunnett’s multiple comparison tests indicated that the following doses and test
compounds significantly reduced response rate compared to saline (P < 0.05): 1.5 mg/kg and 3.0
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mg/kg (-)-MDMA; 0.75, 1.5 and 3.0 mg/kg (+)-MDA; 1.5 and 3.0 mg/kg (-)-MDA; 0.75, 1.5 and
3.0 mg/kg (±)-MDMA; 1.5 and 3.0 mg/kg (±)-MDA.

Figure 1. Dose-response curves determined from substitution tests with MDPV, MDMA, MDA
and the optical isomers of MDMA and MDA in rats trained to discriminate 0.5 mg/kg MDPV
from saline. Percentage MDPV-lever selection is depicted by closed symbols in the top row and
response rate is shown as open symbols in the bottom row. Individual data points represent the
group mean (± SEM). N=7 except where noted in parentheses at 3.0 mg/kg for some test
compounds. Statistically significant Dunnett’s tests compared to saline (P < 0.05) are indicated
by a [(±)-MDMA or (±)-MDA], b [(+)-MDMA or (+)-MDA], or c [(-)-MDMA or (-)-MDA].

Cocaine fully substituted for MDPV at 5, 10 and 20 mg/kg and partially substituted at 2.5
mg/kg. The selective atypical DAT inhibitor, GBR 12909 and the NET/SERT inhibitor,
desipramine, failed to substitute for MDPV at the doses tested. Dose-response curves generated
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from stimulus substitution tests with these substances are displayed in Figure 2. A one-way RM
ANOVA revealed a statistically significant effect of cocaine dose on response rate [F(4, 16) =
3.87, P < 0.05]. Dunnett’s multiple comparison tests indicated 5 and 20 mg/kg cocaine lowered
response rate compared to saline (P < 0.05). Neither GBR 12909 [F(4, 20) = 1.04, P = 0.41] nor
desipramine [F(3, 12) = 1.31, P = 0.32] significantly reduced response rate.

Figure 2. Dose-response curves generated from stimulus substitution tests with cocaine (n=5),
GBR 12909 (n=6), and desipramine (n=5). Percentage MDPV-associated lever responses (closed
symbols) refers to the left Y-axis and response rate (open symbols) refers to the right Y-axis.
Individual points represent the group mean (± SEM). Statistically significant Dunnett’s tests
compared to saline are indicated by * (P < 0.05).

Stimulus Potentiation
Figure 3 displays the dose-response curves generated from stimulus potentiation tests
with vehicle (n=5), 3.2 mg/kg desipramine (n=5), and 40 mg/kg GBR 12909 (n=4) pretreatment
with each dose of MDPV. The vehicle + MDPV dose-response curve was nearly identical to the
MDPV dose-response curve determined previously. Desipramine 3.2 mg/kg pretreatment with
0.1 mg/kg MDPV also produced complete substitution for MDPV (Rat-A: 18.52%, Rat-B:
100%, Rat-C: 100%, Rat-D: 100%, Rat-E: 95.45%). Pretreatment with 40 mg/kg GBR 12909
13

and MDPV 0.05 mg/kg produced complete stimulus substitution for MDPV, although only
partial substitution was obtained with GBR 12909 + 0.1 mg/kg MDPV (n=3). Variability within
subjects was observed with pretreatment of 40 mg/kg GBR 12909 and vehicle (Rat-B: 100%,
Rat-C: 4.55%, Rat-D: 0%, Rat-E: 100%), as well as with GBR 12909 and 0.1 mg/kg of MDPV
(Rat-A: 100%, Rat-B: 8.7%, Rat-C: 100%, Rat-D: n/a), which can be depicted from the error
bars in Figure 3. Rat-D did not meet the response requirement during the test session with 40
mg/kg GBR 12909 + 0.1 mg/kg MDPV pretreatment that is needed to calculate the percentage of
MDPV-appropriate lever selection. A RM ANOVA indicated no statistically significant changes
in response rate compared to vehicle were produced by GBR 12909 + MDPV [F(3, 9) = 0.73, P
= 0.56] or by desipramine + MDPV [F(3, 12) = 1.95, P = 0.18]. ED50 values were not
determined due to an insufficient number of doses assessed to yield unambiguous results.

Figure 3. MDPV dose-response curves determined with saline (n=5), 40 mg/kg GBR 12909
(n=4, n=3 for percentage of MDPV-associated lever selection with 40 mg/kg GBR 12909 +
MDPV at the 0.1 mg/kg dose), or 3.2 desipramine (n=5) pre-treatment. Percentage MDPV-lever
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selection is depicted by closed symbols (left graph) and response rate is depicted as open
symbols (rightward graph). Individual points represent group mean (± SEM).

Experiment 2
MDPV produced a dose-dependent increase in MDPV-lever responding, with full
substitution produced by 0.3, and 1.0 mg/kg (training dose) (Figure 4). Dose-response curves
generated with MDPV and each antagonist are displayed in Figure 5.

Figure 4. Dose-response curve for MDPV. Percentage MDPV-lever responses (closed symbols)
refers to the left Y-axis and response rate (open symbols) refers to the right Y-axis.
Individual points represent group mean (± SEM).

Dopamine Receptor Antagonists
The selective D1 dopamine antagonist, Sch 23390 and the prototypical D2 antagonist,
haloperidol dose-dependently attenuated MDPV-lever selection. Full blockade of 1.0 mg/kg
MDPV discrimination was observed with Sch 23390 0.1 mg/kg. A higher Sch 23390 dose (0.3
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mg/kg) disrupted responding in nearly half of the 1.0 mg/kg MDPV-trained animals. Haloperidol
produced only partial antagonism of 1.0 mg/kg MDPV at the highest dose tested (0.5 mg/kg).
A dose-dependent decrease in response rate was observed following tests with Sch 23390
and haloperidol. A one-way RM ANOVA found a statistically significant reduction in response
rate following pretreatment with Sch 23390 and 1.0 mg/kg MDPV [F(4, 24) = 4.17, P < 0.05].
Dunnett’s multiple comparison tests indicated that only the highest dose of Sch 23390 (0.3
mg/kg) reduced response rate to a level that was significantly different from response rate
following saline pretreatment with 1.0 mg/kg MDPV (P < 0.01). One-way RM ANOVA tests
did not find any statistically significant effects on response rates following the administration of
haloperidol [F(3, 18) = 0.82, P = 0.50].
Serotonin Receptor Antagonists
The 5-HT2 antagonist, pirenperone, the 5-HT2A antagonist, MDL 100,907, and the 5HT1A antagonist WAY 100,635 did not alter 1.0 mg/kg MDPV discrimination. Response rate
was not significantly different from control rates following pirenperone [F(3, 12) = 2.23, P =
0.14], MDL 100,907 [F(3, 15) = 1.38, P = 0.29], or WAY 100,635 [F(3, 15) = 0.79, P = 0.52].
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Figure 5. Stimulus antagonism tests with Sch 23390, haloperidol, pirenperone, MDL 100,907,
and WAY 100,635 administered with 1.0 mg/kg MDPV are graphed above. Percentage of
MDPV-appropriate lever responses (closed symbols) is represented in the top graph, with
response rate (open symbols) represented in the lower graph. Individual points represent group
mean (± SEM). Statistically significant Dunnett’s tests compared to saline are indicated by * (P <
0.05).
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CHAPTER IV
DISCUSSION
The current study examined the contribution of monoaminergic mechanisms in mediating
the discriminative stimulus effects of the synthetic cathinone, MDPV through the assessment of
stimulus substitution with 5-HT/DA releasers (MDMA, MDA and their optical isomers), a
typical DAT inhibitor (cocaine), a highly selective atypical DAT inhibitor (GBR 12909), and a
SERT/NET inhibitor (desipramine) in rats trained to discriminate 0.5 mg/kg MDPV (Experiment
1), and through the assessment of DA and 5-HT antagonists in rats trained to discriminate 1.0
mg/kg MDPV (Experiment 2).
Full substitution for MDPV was observed with cocaine, the racemates of MDMA and
MDA, as well as (+)-MDMA. Only partial substitution was obtained with (+)-MDA at a dose
that markedly reduced response rate, whereas (-)-MDMA and (-)-MDA produced virtually no
substitution for MDPV. In consideration of previous evidence that the (+)-optical isomers of
MDMA and MDA are more dopaminergic and the (-)-optical isomers are more serotonergic
(Baker et al., 1995; Broadbent et al., 1992; Callahan & Appel, 1988; Glennon & Young, 1984),
the current findings suggest MDPV discrimination is mediated to a greater extent by
dopaminergic than serotonergic actions. Complete stimulus substitution by cocaine further
supports this hypothesis and is consistent with previous reports regarding similarities in the
interoceptive stimulus effects of MDPV and cocaine (Gatch et al., 2013; Gannon et al., 2016;
Berquist & Baker, 2017). However, the absence of stimulus substitution by GBR 12909 indicates
DAT inhibition alone is not sufficient to produce the MDPV cue.
The seemingly disparate results with cocaine and GBR 12909 in the current study may be
due to cocaine’s less selective, passive reuptake inhibition of DA, NE, and 5-HT compared to the
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selective, atypical DAT inhibition by GBR 12909 (Andersen, 1989; Matecka et al., 1996).
Curiously, GBR 12909 was reported to produce complete stimulus substitution for cocaine
(Cunningham & Callahan 1991). However, rats can be trained to discriminate cocaine from GBR
12909 (Tella & Goldberg, 2001). Clearly, the training dose used to establish stimulus
discrimination influences stimulus generalization to similar drugs.
Full substitution with (±)-MDMA for MDPV in the current study is consistent with
previous findings reported by Fantegrossi et al. (2013) in a study of mice trained to discriminate
0.3 mg/kg MDPV, but contradict more recent findings reported by Berquist & Baker (2017) who
trained rats to discriminate 0.3 mg/kg MDPV. Although the species and training procedures of
the current study were similar to those reported by Berquist & Baker (2017), the training dose
was slightly higher in the current study. A systematic evaluation of MDPV training dose may be
required to determine if the training dose or other factors (e.g., order of test compounds assessed)
account for the discrepant results.
As previously noted, the absence of MDPV stimulus substitution by GBR 12909 or by
the tricyclic antidepressant, desipramine indicates that neither DAT nor NET/SERT inhibition
alone is sufficient to produce the MDPV cue. Of particular interest, both GBR 12909 and
desipramine pretreatment appeared to potentiate MDPV discrimination, indicative that both DAT
and NET/SERT activities may modulate the actions of MDPV. Curiously, 40 mg/kg GBR 12909
pretreatment with vehicle tests produced an average of 51% MDPV-lever selection, substituting
completely in two of the four animals tested. No dose of GBR 12909 produced even partial
substitution when this substance was previously tested alone for substitution. However, the
current results with GBR 12909 pretreatment should be considered with caution, as these tests
were completed four months after the completion of initial GBR 12909 dose-response tests and
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only four of the seven original animals were included in these tests (inconsistent responding,
most likely due to age). It is possible that with more extensive training or with age, the animals
developed greater sensitivity to the effects of GBR 12909. However, greater sensitivity to lower
doses of MDPV were not evident, as the MDPV dose-response curve generated with vehicle
pretreatments was nearly identical to the initial dose-response curve determined with MDPV at
the beginning of the study. At the very least, these preliminary findings may serve to prompt
further investigation. Results from the potentiation test conducted could be interpreted to suggest
concurrent use of MDPV with monoamine reuptake inhibitors may have additive effects and
perhaps an enhanced risk for abuse. Further investigation with a wider range of doses and with
other selective monamine reuptake inhibitors are required to fully assess whether these
substances have additive or synergistic effects with MDPV.
Results from Experiment 2 exhibiting dose-dependent attenuation and complete
antagonism of MDPV discrimination by Sch 23390 indicate MDPV’s stimulus effects are
mediated primarily by dopamine’s actions at D1 receptors. Partial antagonism by haloperidol
indicate D2 DA receptors also contribute to these effects. In contrast, the absence of stimulus
antagonism by pirenperone, MDL 100,907, and WAY 100,635 suggests a lack of involvement of
5-HT receptor mediation of the MDPV cue. These findings are consistent with previous reports
that MDPV primarily acts as an uptake blocker at the dopamine transporter, with relatively
weaker effects on serotonin release (Baumann et al., 2013; Simmler et al. 2013; Eshleman et al.
2013). It should be noted that the two highest doses of Sch 23390 (0.1 and 0.3 mg/kg) both
attenuated 1.0 mg/kg MDPV discrimination and that only the highest dose (0.3 mg/kg)
significantly reduced response rate. Additional tests with other selective dopamine receptor
antagonists, preferably those that do not produce significant response rate disruption, are
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warranted to determine if the response disruptive effects of Sch 23390 contributed to the
attenuation of MDPV’s discriminative stimulus effects.
In summary, considering the results of the two experiments described herein, complete
stimulus substitution by the typical DAT inhibitor, cocaine and complete antagonism by DA
receptor antagonists, but not 5-HT receptor antagonists, suggest MDPV’s interoceptive stimulus
effects are mediated predominantly by dopaminergic actions, with D1 receptors contributing to
these effects to a greater extent than D2 receptors. However, we cannot rule out the possibility of
serotonergic and/or noradrenergic modulation of these effects, given the substitution by MDMA
and MDA and the potentiation by desipramine. Evaluation of additional DAT and NET
inhibitors for potentiation of the MDPV cue and the assessment of additional antagonists,
preferably with less disruptive effects on responding, may further assist in determining the
precise neurochemical actions responsible for MDPV discrimination. Such knowledge can serve
to inform medication discovery and development for the treatment of MDPV abuse.
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